CLINICAL_TRIALS
trial_result
· 2019-02-19
Clinical Trial Update: GSK1120212 Rollover Study [Phase 2]
Summary
A Phase 2 rollover study of GSK1120212 (trametinib) sponsored by Novartis was terminated, and results were posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-02-19